Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Cytosorbents ( (CTSO) ) is now available.
On July 2, 2025, CytoSorbents Corporation announced regulatory updates regarding its DrugSorb-ATR device. The U.S. FDA scheduled an appeal hearing for the company’s supervisory review, while Health Canada issued a Notice of Refusal for the Medical Device License application due to non-compliance issues. CytoSorbents plans to address these concerns through the appeals process, aiming for final regulatory decisions by the end of 2025. The company believes DrugSorb-ATR offers a unique solution for reducing perioperative bleeding in cardiac surgery, addressing a critical need in the U.S. and Canadian markets.
The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.
Spark’s Take on CTSO Stock
According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.
Cytosorbents’ overall stock score reflects significant financial challenges and a weak valuation outlook, primarily driven by declining revenues, negative cash flows, and high leverage. Despite positive technical indicators and strategic initiatives mentioned in recent earnings calls, the stock’s fundamental weaknesses weigh heavily on its overall attractiveness.
To see Spark’s full report on CTSO stock, click here.
More about Cytosorbents
CytoSorbents Corporation is a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery. The company specializes in proprietary blood purification technologies using biocompatible, highly porous polymer beads to remove toxic substances from blood and other bodily fluids. Their products, including CytoSorb, are used in various applications such as reducing severe bleeding during cardiothoracic surgery and removing inflammatory agents in critical illnesses.
Average Trading Volume: 111,306
Technical Sentiment Signal: Buy
Current Market Cap: $80.77M
For detailed information about CTSO stock, go to TipRanks’ Stock Analysis page.